Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02151474 · ClinicalTrials.gov registry record · Phase 2
INCB047986 in Rheumatoid Arthritis
A Phase 2 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02151474: Clinical Trial Phase 2 study, sponsored by Incyte Corporation.
NCT02151474 is a Phase 2 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02151474, a Phase 2 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to explore the safety, tolerability and efficacy of INCB047986, in subjects with moderate to severe rheumatoid arthritis.
Interventions
- DRUG Placebo
- DRUG INCB047986
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-05 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Why NCT02151474 stopped before completion
NCT02151474 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02151474 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02151474 about?
NCT02151474 is a clinical study titled "INCB047986 in Rheumatoid Arthritis". The purpose of this study is to explore the safety, tolerability and efficacy of INCB047986, in subjects with moderate to severe rheumatoid arthritis.
What is the current status of trial NCT02151474?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2014-05. Estimated completion is 2014-08.
What interventions are being tested in trial NCT02151474?
The interventions under investigation include: Placebo (DRUG), INCB047986 (DRUG).
Who is sponsoring clinical trial NCT02151474?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02151474's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia